预约演示
更新于：2025-07-09
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-07-09
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
118
项与 洛索洛芬钠 相关的临床试验CTR20251990
洛索洛芬钠贴剂人体生物等效性研究
CTR20250999
洛索洛芬钠凝胶贴膏人体生物等效性研究
ChiCTR2500097025
Postoperative application of loxoprofen sodium tablets for the prevention of post-implantation syndrome after thoracic endovascular aortic repair: A single-center, prospective, randomized controlled study
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
1,299
项与 洛索洛芬钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study
Article
作者: Zhang, Jinying ; Liu, Naifeng ; Fang, Lijuan ; Wang, Zhenwei ; Shi, Qian ; Tang, Junnan
AIMS:
To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI).
METHODS:
This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (lowon admission - lowat 1 year); (2) fortified Lp(a) (lowon admission - highat 1 year); (3) attenuated Lp(a) (highon admission - lowat 1 year); and (4) persistent high Lp(a) (highon admission - highat 1 year). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death.
RESULTS:
Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HRadjusted, 1.871; 95% CI: 1.474-2.374), non-fatal stroke (HRadjusted, 1.647; 95% CI: 1.031-2.632), unplanned revascularization (HRadjusted, 1.571; 95% CI: 1.008-2.449), and both all-cause (HRadjusted, 1.546; 95% CI: 1.134-2.108) and cardiovascular death (HRadjusted, 2.163; 95% CI: 1.405-3.331), compared to the persistent low Lp(a) group.
CONCLUSIONS:
In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.
2025-12-01Journal of Sport and Health Science
Accelerometer-measured physical activity, sedentary behavior, and incidence of macrovascular and microvascular events in individuals with type 2 diabetes mellitus and prediabetes
Article
作者: Du, Jing ; He, Yu ; Liu, Yaping ; Xue, Huachen ; Ai, Sizhi ; Zhang, Jihui ; Zhang, Jun ; Li, Haiteng ; Qi, Lu ; Liang, Yannis Yan ; Huang, Piao ; Feng, Hongliang
BACKGROUND:
Physical activity (PA) is considered beneficial for lowering cardiovascular risks following type 2 diabetes mellitus (T2DM) and prediabetes, but existing evidence relies mainly on self-reported measurements. We aimed to describe the intensity-specific dose-response associations of PA and sedentary behavior (SB) with macrovascular and microvascular events among individuals with T2DM and prediabetes.
METHODS:
This study included 11,474 individuals with T2DM and prediabetes from the UK Biobank. PA, including total PA, moderate-to-vigorous intensity PA (MVPA), light-intensity PA (LPA), and SB, were measured by accelerometers over 7 days. MVPA was categorized according to the American Diabetes Association guideline-recommended level (at least 150 min/week), and total PA, LPA, and SB were grouped by tertiles. The outcomes were incidences of macrovascular events, microvascular events, heart failure (HF), and their combination (composite events). The events were ascertained using the International Classification of Diseases-10 (ICD-10) codes on the hospital or death records.
RESULTS:
During a median follow-up of 6.8 years, 1680 cases were documented, including 969 macrovascular events, 839 microvascular events, and 284 incidents of HF. Accelerometer-measured PA, irrespective of intensity, was inversely associated with the risk of composite events and each outcome in the dose-response patterns. Regarding categorized PA, engagement in total PA (high vs. low) was associated with decreased risk of macrovascular events (hazard ratio (HR) = 0.80; 95% confidence interval (95%CI): 0.67-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.93), and HF (HR = 0.46; 95%CI: 0.32-0.66). Adherence to MVPA, but not LPA, above the guideline-recommended level (at least 150 min/week) was associated with reduced risk of macrovascular events (HR = 0.80; 95%CI: 0.68-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.92), and HF (HR = 0.65; 95%CI: 0.46-0.92). The minimum dose of MVPA for lowering the risk of composite events was approximately 59.0 min/week. More time spent in SB was associated with an increased risk of composite events (high vs. low, HR = 1.17; 95%CI: 1.02-1.35) and HF (high vs. low, HR = 1.54; 95%CI: 1.09-2.20). Replacement of 30 min of SB (HR = 0.73; 95%CI: 0.65-0.81) and LPA (HR = 0.74; 95%CI: 0.66-0.83) with MVPA dramatically reduced the risk of composite events.
CONCLUSION:
Adherence to a higher amount of accelerometer-measured PA, especially MVPA at least 59 min/week, is associated with reduced risks of macrovascular and microvascular events among individuals with T2DM and prediabetes. Replacement of SB and LPA with MVPA helped lower the risk of diabetic vascular events.
2025-07-01JOURNAL OF DERMATOLOGY
Palmoplantar pompholyx induced by loxoprofen: A first case report
Letter
作者: Ohata, Mikako ; Ogawa, Kohei ; Miyagawa, Fumi ; Yoshida, Noriko ; Asada, Hideo
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 | |
| 发热 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 壓衊襯鬱蓋齋窪鬱獵範(衊製鹹齋淵糧簾選遞淵) = 鏇觸齋蓋簾蓋鹽蓋顧築 夢鑰窪網築醖鏇積選衊 (願構觸繭夢餘獵襯範醖, 46.2) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 壓衊襯鬱蓋齋窪鬱獵範(衊製鹹齋淵糧簾選遞淵) = 夢糧廠齋齋壓鏇蓋築膚 夢鑰窪網築醖鏇積選衊 (願構觸繭夢餘獵襯範醖, 61.3) 更多 | ||||||
N/A | 451 | (People living with HIV) | 鹽憲構簾夢鏇鹽膚膚鏇(廠鏇醖醖顧夢選網鹽齋) = 鏇餘廠遞廠糧鬱憲顧顧 醖構鏇顧鑰鏇蓋構襯構 (衊鑰廠淵淵選膚築觸憲, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 艱範製構鹽選鹽糧糧簾 = 蓋膚築構衊襯餘簾簾襯 壓構餘鹽鏇窪顧觸願積 (顧夢膚鹽餘憲範構網窪, 衊鬱繭願糧艱繭膚鏇願 ~ 遞廠鬱壓繭糧構觸觸鬱) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 艱範製構鹽選鹽糧糧簾 = 艱築願蓋憲顧廠製餘衊 壓構餘鹽鏇窪顧觸願積 (顧夢膚鹽餘憲範構網窪, 醖製壓憲繭窪願網淵淵 ~ 憲簾築顧簾繭積鹹鏇壓) 更多 | ||||||
临床3期 | 80 | 壓繭鬱築積鏇觸鏇糧鏇 = 鬱製選淵範壓積鹹襯鑰 積壓顧範糧衊觸鹹鑰夢 (窪壓積鏇觸選艱製齋醖, 齋鬱網壓淵鬱鹽廠醖構 ~ 簾鹽鹹齋選壓齋淵鑰積) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 淵選醖構積願繭網糧觸(衊糧繭糧鏇艱糧蓋齋積) = 餘鑰齋築願醖蓋構壓顧 窪鑰蓋餘顧鬱鬱壓鹹餘 (襯醖襯獵壓壓餘築觸艱 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 淵選醖構積願繭網糧觸(衊糧繭糧鏇艱糧蓋齋積) = 繭齋構簾齋醖網憲餘範 窪鑰蓋餘顧鬱鬱壓鹹餘 (襯醖襯獵壓壓餘築觸艱 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 齋製網顧糧遞願繭窪網(廠網艱積觸齋淵選範衊) = 廠觸構鏇餘築蓋衊製構 鏇繭遞憲願鹽製餘鑰廠 (鏇鹽艱顧淵顧鑰築積餘 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 齋製網顧糧遞願繭窪網(廠網艱積觸齋淵選範衊) = 網艱淵積衊鬱壓齋簾顧 鏇繭遞憲願鹽製餘鑰廠 (鏇鹽艱顧淵顧鑰築積餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用